10 documents found, page 1 of 1

Concepts for the Development of Person-Centered, Digitally Enabled, Artificial ...

Abstract The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients' resources and abilities to be experts in their own lives based on their lived experiences. Improving healthcare safety, quality, and coordination, as well as quality of life, is an important aim in the care of patients with chronic conditions. Person-centered care needs to ensure th...

Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The ...

Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air ®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air ® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air ® data, assessing the weeks fo...

Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Contro...

EQ-5D-5L (EuroQOL, 5 Domains, 5 Levels) is a widely used health-related quality-of-life instrument, comprising 5 domains. However, it is not known how each domain is impacted by rhinitis or asthma control.; This study was partly funded by a grant from the University of Liège, Belgium. MASK-air has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Région Languedoc Roussillon and ...

Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: ...

MASK-air® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Econo...

Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: ...

MASK‐air®, a validated mHealth app (Medical Device regulationClass IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. Itis also a candidate Good Practice ofOECD (Organisation for EconomicC...

Patient‐centered digital biomarkers for allergic respiratory diseases and asthm...

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/ or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including m...

Patient-centered digital biomarkers for allergic respiratory diseases and asthm...

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mH...

Management of anaphylaxis due to COVID-19 vaccines in the elderly

Older adults, especially men and/or those with diabetes, hypertension and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritised to receive COVID-19 vaccines due to high risk of death. In very rare instances,the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered c...

ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

Allergen immunotherapy (AIT), the gradually increasing repeated administration of high doses of allergens to allergic patients, offers the potential for immune tolerance against reactions to the natural exposures to specific allergens. AIT may lead to the long‐lasting remission of allergic symptoms and is the only disease‐modifying intervention in IgE‐mediated allergic respiratory diseases. [...]

ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy